Immune Therapeutics, Inc. (IMUN) Offers Update on Methionine-Enkelphine Drug Development Program in China
Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) offered shareholders an update of the status of its ongoing drug development program in China. Recently, Chinese Peptide Company (CPC), one of only a handful of companies in the world that can claim both ISO Certification and cGMP licensing, completed the formulation and required Chemistry, Manufacturing and Controls (CMC) for Methionine-Enkelphine (MENK). IMUN’s long-term partner, Hubei Qianjiang Pharmaceutical Co. Ltd. (Qianjiang), is expected to provide formulation and CMC data to Cytocom, Inc., a subsidiary of IMUN, within 30 days. With this data in hand, Cytocom will take the necessary steps to present final protocols to the FDA for the treatment of pancreatic, pediatric and adult hepatic cancer.
In addition to CMC data, preclinical studies have also been conducted evaluating the pharmacological properties of MENK and tumor response in mice with transplanted cancers. These trials determined a favorable response to MENK against a number of different cancer tumors. Following translation, the results from these studies will also be included in Cytocom’s upcoming FDA briefing package for pediatric and adult hepatic cancer.
IMUN’s efforts to obtain FDA approval for MENK in the United States are also playing a role in efforts to obtain approval for the drug candidate in China. As of April 1, 2016, the company provided Qianjiang all correspondence between IMUN and the FDA regarding the MENK drug development program. MENK, sometimes referred to as opioid growth factor, has been studied by a number of scientists, but the most published of these are Dr. Ian Zagon and his team from Pennsylvania State Medical Center at Hershey. According to Zagon’s research, MENK has been show to regulate the growth of cancer cells, effectively delaying the replication of cells and allowing immunological mechanisms to accomplish the task of destroying cancerous cells.
By seeking clinical approval of MENK in both the U.S. and China, IMUN is well-positioned to enter two of the largest pharmaceutical markets in the world. According to the Economist Intelligence Unit, drug sales in China are expects to top $166 billion by 2017, providing a recognized market to further growth. Despite its tremendous size, China’s pharmaceutical industry is not yet fully mature. Within the next decade, economic and demographic development, government stimulus, enhanced health awareness among the public, market consolidation and improved R&D capabilities are expected to transform the Chinese pharmaceutical industry into a sophisticated market.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) offered shareholders an update of the status of its ongoing drug development program in China. Recently, Chinese Peptide Company (CPC), one of only a handful of companies in the world that can claim both ISO Certification and cGMP licensing, completed the formulation and required Chemistry, Manufacturing and Controls (CMC) for Methionine-Enkelphine (MENK). IMUN’s long-term partner, Hubei Qianjiang Pharmaceutical Co. Ltd. (Qianjiang), is expected to provide formulation and CMC data to Cytocom, Inc., a subsidiary of IMUN, within 30 days. With this data in hand, Cytocom will take the necessary steps to present final protocols to the FDA for the treatment of pancreatic, pediatric and adult hepatic cancer.
In addition to CMC data, preclinical studies have also been conducted evaluating the pharmacological properties of MENK and tumor response in mice with transplanted cancers. These trials determined a favorable response to MENK against a number of different cancer tumors. Following translation, the results from these studies will also be included in Cytocom’s upcoming FDA briefing package for pediatric and adult hepatic cancer.
IMUN’s efforts to obtain FDA approval for MENK in the United States are also playing a role in efforts to obtain approval for the drug candidate in China. As of April 1, 2016, the company provided Qianjiang all correspondence between IMUN and the FDA regarding the MENK drug development program. MENK, sometimes referred to as opioid growth factor, has been studied by a number of scientists, but the most published of these are Dr. Ian Zagon and his team from Pennsylvania State Medical Center at Hershey. According to Zagon’s research, MENK has been show to regulate the growth of cancer cells, effectively delaying the replication of cells and allowing immunological mechanisms to accomplish the task of destroying cancerous cells.
By seeking clinical approval of MENK in both the U.S. and China, IMUN is well-positioned to enter two of the largest pharmaceutical markets in the world. According to the Economist Intelligence Unit, drug sales in China are expects to top $166 billion by 2017, providing a recognized market to further growth. Despite its tremendous size, China’s pharmaceutical industry is not yet fully mature. Within the next decade, economic and demographic development, government stimulus, enhanced health awareness among the public, market consolidation and improved R&D capabilities are expected to transform the Chinese pharmaceutical industry into a sophisticated market.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
